11 completed, 2 terminated. 10 Phase 2, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 2 |
| Not applicable | 3 | Completed 3 |
Follow Alkahest, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI) AKST4290, Placebo - Diabetic Retinopathy | Phase 2 | Terminated | Alkahest, Inc. | 3 | 2021-08-17 | 2023-11-01 |
| Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis AKST1210 S-15 at 250 mL/min, AKST1210 S-15 at 450 mL/min, AKST1210 S-25 at 250 mL/min - End-Stage Renal Disease | Not applicable | Completed | Alkahest, Inc. | 10 | 2021-03-11 | 2023-09-29 |
| A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment AKST1210, Sham Control (No Intervention), Hemodialysis - Cognitive Impairment, End Stage Renal Disease | Not applicable | Completed | Alkahest, Inc. | 10 | 2020-04-28 | 2022-12-12 |
| A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid Mometasone furoate, AKST4290, Placebo - Pemphigoid, Bullous | Phase 2 | Terminated | Alkahest, Inc. | 6 | 2020-01-30 | 2023-09-14 |
| A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD AKST4290, Placebo, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Alkahest, Inc. | 107 | 2020-01-28 | 2022-10-26 |
| Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment AKST4290, Placebo - Parkinson Disease | Phase 2 | Completed | Alkahest, Inc. | 110 | 2020-01-16 | 2022-10-10 |
| A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty GRF6021, Placebo - Postoperative Recovery | Phase 2 | Completed | Alkahest, Inc. | 38 | 2019-07-12 | 2024-03-13 |
| A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease GRF6019, Placebo - Severe Alzheimer Disease | Phase 2 | Completed | Alkahest, Inc. | 26 | 2019-01-15 | 2021-01-27 |
| A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment GRF6021, Placebo - Parkinson Disease | Phase 2 | Completed | Alkahest, Inc. | 79 | 2018-11-12 | 2022-05-09 |
| Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration ALK4290 - Wet Age-related Macular Degeneration | Phase 2 | Completed | Alkahest, Inc. | 26 | 2018-04-20 | 2020-12-22 |
| A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease GRF6019 - Alzheimer Disease, Mild to Moderate Alzheimer Disease | Phase 2 | Completed | Alkahest, Inc. | 47 | 2018-04-16 | 2021-01-29 |
| Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration ALK4290 - Wet Age-related Macular Degeneration | Phase 2 | Completed | Alkahest, Inc. | 30 | 2018-04-04 | 2020-12-16 |
| The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study Plasma - Mild-To-Moderate Alzheimer's Disease, Alzheimer's Disease | Not applicable | Completed | Stanford University | 18 | 2014-09-01 | 2017-10-10 |
Alzheimer Disease (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Dementia (3) · Mental Disorders (3) · Nervous System Diseases (3) · Neurocognitive Disorders (3) · Neurodegenerative Diseases (3) · Kidney Failure, Chronic (2) · Parkinson Disease (2) · Autoimmune Diseases (1) · Cognition Disorders (1) · Cognitive Dysfunction (1) · Diabetic Retinopathy (1) · Eye Diseases (1)
Mometasone Furoate (1) · Renal Dialysis (1) · Saline Solution (1) · aflibercept (1)
United States (10) · Germany (3) · Hungary (3) · Poland (2) · Australia (1) · Estonia (1) · France (1) · Slovakia (1)